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Significant morbidity and mortality among patients with diabetes
mellitus result largely from a greatly increased incidence of micro-
vascular complications. Proliferative diabetic retinopathy (PDR)
and end stage renal disease (ESRD) are two of the most common
and severe microvascular complications of diabetes. A high con-
cordance exists in the development of PDR and ESRD in diabetic
patients, as well as strong familial aggregation of these complica-
tions, suggesting a common underlying genetic mechanism. How-
ever, the precise gene(s) and genetic variant(s) involved remain
largely unknown. Erythropoietin (EPO) is a potent angiogenic
factor observed in the diabetic human and mouse eye. By a
combination of case–control association and functional studies,we
demonstrate that the T allele of SNP rs1617640 in the promoter of
the EPO gene is significantly associatedwith PDR and ESRD in three
European-American cohorts [Utah: P  1.91  103; Genetics of
Kidneys in Diabetes (GoKinD) Study: P  2.66  108; and Boston:
P 2.1 102]. The EPO concentration in human vitreous bodywas
7.5-fold higher in normal subjects with the TT risk genotype than
in those with the GG genotype. Computational analysis suggests
that the risk allele (T) of rs1617640 creates a matrix match with the
EVI1/MEL1 or AP1 binding site, accounting for an observed 25-fold
enhancement of luciferase reporter expression as compared with
the G allele. These results suggest that rs1617640 in the EPO
promoter is significantly associated with PDR and ESRD. This study
identifies a disease risk-associated gene and potential pathway
mediating severe diabetic microvascular complications.
diabetic microvascular complication  end stage renal disease 
proliferative diabetic retinopathy  SNP  association
The prevalence of diabetes is steadily increasing, and currentU.S. and international figures (18 and 171 million people,
respectively) are expected to increase to 30 and 366 million
people, respectively, by the year 2030 (1). Despite multiple
current therapeutic approaches, diabetic complications remain a
major cause of morbidity and mortality. Microvascular compli-
cations, including retinopathy and nephropathy, account for the
most prevalent and severe morbidity associated with diabetes
and may be involved in mediating the increased risk of cardio-
and cerebrovascular disease as well. A prominent sight-
threatening form of diabetic retinopathy, proliferative diabetic
retinopathy (PDR), is the most common and severe cause of
new-onset legal blindness in working-aged adults in the United
States and accounts for 10% of new-onset blindness overall.
Diabetes is also the leading cause of renal insufficiency and
end-stage renal disease (ESRD) in the United States and the
Western world. Although PDR and ESRD are clearly associated
with the degree of hyperglycemia, not all diabetic individuals
with poor glycemic control develop advanced retinal or renal
complications. Conversely, some patients develop severe com-
plications despite well controlled blood glucose concentrations
(2). The underlying etiology of these microvascular complica-
tions remains poorly understood.
A well documented high concordance rate (80–90%) between
PDR and ESRD underscores a potentially shared pathophysi-
ology (3). PDR, characterized by neovascularization and fibrous
proliferation, can ultimately result in tractional retinal detach-
ment and vitreous hemorrhage [supporting information (SI) Fig.
S1A andB]. The onset of PDR is thought to occur primarily after
progressive retinal ischemia produces increased expression of
the hypoxia-inducible vascular endothelial growth factor
(VEGF), leading to retinal vascular proliferation and perme-
ability (4, 5). Although nearly all patients with diabetes will
develop some degree of retinopathy in their lifetimes, PDR
occurs only in approximately half (6).
The high degree of familial aggregation and concordance in
the development of PDR and ESRD in diabetic patients implies
that common genetic factors may be important in susceptibility
(or resistance) to these complications (3, 7, 8). However, the
causal gene(s) remains largely unknown. A growing number of
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genome-wide linkage scans have been performed to detect
diabetic nephropathy susceptibility loci. Case–control studies
have examined possible roles for various candidate gene single-
nucleotide polymorphisms (SNPs), and linkage analysis has
suggested a diabetic nephropathy locus on chromosome 3q
(9–11). Other loci have also been suggested (reviewed in ref. 11).
Recently, several reports implicate a locus at chromosome 7q21
as a modifier of the risk of nephropathy in diabetes (11–14), but
a specific gene has not been identified.
The various intermediate phenotypes between the extremes of
no nephropathy and diabetic ESRD (Fig. S1C) could affect the
results of genome-wide linkage scans. These phenotypes include
microalbuminuria without frank proteinuria, proteinuria and/or
microalbuminuria with normal renal filtration, frank proteinuria
and nephrosis with or without renal insufficiency, and renal
failure. Although proteinuria is generally regarded as a key
feature of diabetic nephropathy, some large epidemiological
studies also report an increase in diabetic non-proteinuric kidney
disease (15). Thus, it is possible that the criteria by which the
nonspecific diagnosis ‘‘diabetic nephropathy’’ is defined may
have increased phenotypic as well as genetic heterogeneity.
Diabetes may harm the eye and kidney through multiple direct
and indirect mechanisms. We reasoned that by considering as
‘‘cases’’ only those individuals with the combined severe micro-
vascular complication phenotypes of both ESRD and PDR we
would reduce genetic heterogeneity and increase the likelihood
of detecting a genetic effect.
To test whether variants in genes involved in angiogenesis
increase susceptibility to diabetic microvascular complications,
we genotyped 19 SNPs from 11 candidate genes in diabetic
patients with or without PDR and ESRD and tested for allelic
associations. We also performed functional studies on an EPO
promoter, SNP rs1617640, which was associated with diabetic
complications in three cohorts.
Results
Genetic Association Study. We genotyped 19 SNPs in 11 genes
involved in angiogenesis in 374 patients with both PDR and
ESRD and 239 age- and ethnicity-matched diabetic controls
from a Utah European-American type 2 diabetes (T2D) cohort
(Table S1). No significant association was found (Table S2)
except at SNP rs1617640 (Fig. 1A, P  1.91  103 for an
additive allele-dosage model, ORhet 1.20 [0.76, 1.89], ORhom
2.01 [1.23, 3.29], T allele: 63.10% in cases versus 54.18% in
controls, Table 1). This association remained significant after
Bonferroni correction for multiple comparisons (P  0.036).
To investigate whether rs1617640 was specifically associated
with diabetic microvascular complications, rather than compli-
cations of T2D per se, we sought to replicate this result in two
other independent type 1 diabetes (T1D) cohorts; the GoKinD
and Boston cohorts. We chose only European-American indi-
viduals in the GoKinD collection and excluded patients or
controls with other ethnicities. In total, there were 865 cases in
the GoKinD cohort, including 365 T1D patients with both
ESRD and PDR, 500 with nephropathy (proteinuria with urine
albumin to creatinine ratio 300) and retinopathy without
progression to PDR and ESRD, and 574 T1D diabetic control
patients without retinopathy and nephropathy (16). We ob-
served significant association from patients with PDR and
ESRD (P 1.04 106, allelic model, ORhet 1.19[0.81, 1.73],
ORhom  2.38 [1.60, 3.54], T allele: 63.97% in cases versus
52.53% in controls, Table S4). The association extended to T1D
individuals with significant nephropathy and retinopathy but
who have not progressed to ESRD (500 cases, P  6.25  106,
Table S4). Overall, there is a strong association in the GoKinD
European-American cohort based on allele-frequency differ-
ence in cases and controls (P  2.66  108, Table 1). We also
observed significant association (P  2.1  102, Table 1) in
another independent Boston European-American T1D cohort.
This cohort includes 379 patients who have both PDR and
nephropathy and 141 diabetic control patients of European-
American ethnicity.
Hidden subdivision (stratification) can induce false-positive
associations in case–control studies (17). This effect has been
Fig. 1. Genetic association. (A) Negative log P values (y axis) from association
analyses for 11 SNPs in the chromosome 7q22 region harboring the EPO gene
(see also Table S3). The violet squares represent all SNPs around rs1617640
from the Utah T2D cohort. The green square represents rs1617640 from the
Boston T1D cohort. The pink square represents rs1617640 from the Utah T2D
cohort. The light blue square represents rs1617640 from the GoKinD patients
who have retinopathy and nephropathy but have not progressed into ESRD.
The red square represents rs1617640 from the GoKinD patients who have both
PDR and ESRD. The black square represents rs1617640 from the GoKinD
cohort. (B) Genomic structure and locations of genes between base pairs 99.94
and 100.04 million (National Center for Biotechnology Information build 35).
(C) Pairwise D and R2 Haploview (38) plots for SNPs in chromosome 7 in the
region around the EPO gene when Utah T2D case and control data are used.






minimized by our choice of European-American case–control
cohorts derived from limited, distinct geographic areas in the
United States (GoKinD cohort: Boston, Pittsburgh, and Min-
nesota; Utah cohort: Salt Lake City; Boston cohort: Boston). In
particular, our initial Utah T2D cohort are all Utahns of
European descent, known to be genetically homogeneous and
very similar genetically to the British and Scandinavian popu-
lations from whom they were derived (18, 19). An analysis of
subdivision in eight dispersed geographic samples from Utah
demonstrated that only 1% of genetic variation can be attributed
to subdivision effects (20). This slight degree of subdivision is
highly unlikely to cause the strong association observed in the
Utah case–control study. Furthermore, it is improbable that the
same stratification effect would be seen in the two independent
replication cohorts.
Haplotype Analysis. rs551238 is in high linkage disequilibrium
(LD) with rs1617640 (D  0.89, and R2 0.75) and also exhibits
a significant case–control difference in the Utah cohort (P 
1.7  102, Table S3). We observed a disease-associated hap-
lotype, TTA, of SNPs rs1617640, rs507392, and rs551238 (59.5%
in patients, 49.5% in controls, P 5.00 104, Table S5). These
SNPs exhibited high LD with each other in both case and control
groups (Fig. 1C, which was generated by using Haploview 3.32).
Two additional SNPs, rs734908 and rs4729607, are also in high
LD with rs1617640, rs507392, and rs551238 in the Utah cohort
(Fig. 1), but not in the GoKinD or Boston cohorts, and were
therefore excluded from further analysis. We also identified a
rare protective haplotype, GTA (2% in cases, 6.8% in controls,
P 1.55 105, Table S5). The TTA disease haplotype was also
identified in the Boston T1D cohort (58% in cases, 48% in
controls, P  5.9  103), whereas another disease haplotype,
TCA, was observed in the GoKinD cohort (20% in cases, 3% in
controls, P  1.18  107). The GTA protective haplotype was
also present in the Boston cohort (2.3% in cases, 6.3% in
controls, 1.9  103) and the GoKinD cohort (1.4% in cases,
5.1% in controls, P  0.023). We identified another protective
haplotype (GCC) in the GoKinD cohort (10.1% in cases, 28.2%
in controls, P  1.17  106). The over-riding difference
between disease and protective haplotypes is T versus G at
rs1617640. Allele T of rs507392 and allele A of rs551238 were
present in both the risk and the protective haplotype, indicating
that the T allele in rs1617640 is the main source of association.
Effects of Different rs1617640 Alleles on EPO Expression. rs1617640
is located 1,125 bp upstream of the EPO transcription start site.
Using MatInspector to scan putative transcription factor binding
sites within this region, we found that the risk allele T creates a
matrix match with the EVI1/MEL1 or AP1 enhancer binding site
(Table S6), suggesting it may confer an increased risk by
influencing EPO expression. EPO protein concentrations were
7.5-fold higher in vitreous samples of nondiabetic individuals
with the TT genotype compared with those with the GG
genotype (Fig. 2, P  0.008). The T allele enhanced luciferase
reporter expression by 25-fold compared with that of the G allele
(Fig. 3, P  4.7  1029). This substantial increase in promoter
activity is probably specifically due to an EVI1/MEL1 or AP1
binding site created by the T allele, because elimination of this
SNP by deletion or substitution of T by other bases (C or A)
resulted in markedly decreased reporter expression (Fig. 3).
These data suggest that the T allele of rs1617640 plays a
significant functional role in EPO expression.
Expression of EPO mRNA in Mouse Retina and Kidney. The db/db
mouse model has been extensively used in studying diabetic
kidney complications (21). Similarly, the oxygen-induced reti-
nopathy (OIR) mouse model has been used extensively in










Phenotype Case Control Case Control Case Control Case Control
Population size, n 374 239 865 574 379 141 1,618 954
GG genotype, n 52 46 111 119 60 28 223 193
GT genotype, n 172 127 419 307 180 78 771 512
TT genotype, n 150 66 335 148 139 35 624 249
Risk allele freq, % 63.10 54.18 62.95 52.53 60.42 52.48 62.39 52.90
HWE P values 0.972 0.554 0.528 0.222 0.991 0.432 0.825 0.0587
Genotypic P values 5.02E-3 9.05E-8 0.037 5.47E-11
Allelic P values 1.91E-3 2.66E-8 0.021 2.76E-11
Recessive P values 1.59E-3 3.27E-5 0.011 1.12E-10
Dominant P values 0.078 6.22E-5 0.276 1.79E-5
ORhet 1.20 [0.758, 1.89] 1.46 [1.09, 1.97] 1.01 [0.639, 1.81] 1.30 [1.04, 1.63]
ORhom 2.01 [1.23, 3.29] 2.43 [1.76, 3.35] 1.85 [1.04, 3.32] 2.17 [1.70, 2.76]
GoKinD, Genetics of Kidneys in Diabetes; HWE, Hardy–Weinberg equilibrium; ORhet and ORhom, odds ratio for heterozygous and homozygous states,
respectively, with 95% confidence interval in brackets.
Fig. 2. Comparison of EPO protein level in the vitreous body of nondiabetic
individuals with TT genotype and GG genotype by an ELISA. Five TT and five
GG samples were used and each sample was assayed three times. The mean
SD is given for each genotype. Significance was examined by using SPSS’s
independent sample t test.
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studying retinal neovascularization (22). Therefore, we investi-
gated EPO expression in the db/db and OIR mouse models.
Consistent with the hypothesis that increased expression of EPO
plays a role in the pathogenesis of diabetic kidney and eye
complications, we demonstrated that the expression of EPO was
increased 3-fold in the kidney of db/db mice (Fig. 4A,
P  0.0022) and in the mouse ischemic retina (Fig. 4B, P 
1.1  107).
Discussion
The present study indicates an association between a functional
EPO promoter polymorphism (rs1617640) and diabetic micro-
vascular complications of the eye and kidney. The T risk allele
is the common allele with comparable allele frequency among
European, Asian, and African populations, indicating the risk
allele may be an ancestral allele (23). Our study design is
confined to a single ethnic group (European-American); there-
fore the conclusion may not be generalizable to other ethnic
groups and heterogeneity might be encountered when combin-
ing T1D and T2D. Further replication studies are needed.
EPO is located on 7q21, and our results are consistent with
previous reports that chromosome 7q21 harbors a locus for
increased susceptibility to diabetic nephropathy (11–14). The
risk allele (T) is associated with elevated EPO in the vitreous
body of the human eye and mouse models of diabetic eye and
kidney complications.
EPO encodes a potent angiogenic factor expressed in the
retina and kidney, and high EPO concentrations in human
vitreous body are strongly associated with PDR (22). In addition,
the EPO mRNA concentration is increased in the mouse model
of ischemia-induced retinal neovascularization (Fig. 4B), and
this neovascularization is suppressed by inhibition of EPO (22).
EPO receptor immunoreactivity was strongly detected in neo-
vascular tissues of PDR eyes (24). These findings combined with
our case–control association study and EPO expression profiles
in human vitreous body and luciferase promoter assays suggest
that the TT variant in diabetic patients may convey increased
EPO expression, resulting in an increased risk for the develop-
ment of diabetic complications in the retina and kidney. Con-
versely, our results imply that localized EPO inhibition within the
eye might have therapeutic potential for treatment or prevention
of PDR.
Previous studies have suggested that variation of gene expres-
sion between alleles is common, and this variation is heritable
and may contribute to human variability, such as disease sus-
ceptibility and drug resistance (for detail see review 25) (26–29).
Almost one-third of promoter variants may alter gene expression
and result in phenotypic variation (30). The effects of different
alleles (T versus G) in the SNP rs1617640 of the EPO promoter
on its expression are consistent with this notion.
EPO also maintains a functional role in erythropoiesis and is
widely used to treat anemia resulting from renal failure or
chemotherapy. In the United States, erythropoietin represents
the largest single drug expense for the Center for Medicare and
Medicaid Services, with spending at approximately one billion
dollars per year (31). Patients with anemia attributable to
chronic renal disease (many of whom have diabetes) and receive
frequent dosing of EPO to maintain higher hemoglobin levels
(13.5 g/dl) have a higher rate of cardiovascular complications
than patients who maintain a lower hemoglobin level (11.3 g/dl)
(32). A similar effect of EPO on accelerating the decline of
kidney function had been suggested by earlier studies (33).
Furthermore, prevalence and severity of PDR have worsened
with increased EPO dosing (34). Recent work indicates that
administration of EPO early in retinal vascular development
protects retinal neuron and vasculature, whereas administration
of EPO during retinal capillary nonperfusion associated with
hypoxia markedly worsens retinal neovascularization in OIR
mice (35). Retinal capillary nonperfusion associated with hyp-
oxia is a hallmark of PDR in humans. Our genotype results
suggest that caution may be warranted when maintaining higher
hemoglobin concentrations by using exogenous EPO treatment
in diabetic patients, because it might accelerate progression to
PDR or ESRD.
Severe diabetic microvascular complications, including both
PDR and ESRD, are also strong predictors of cardiovascular
disease and mortality and are associated with a 10-year survival
rate of 10% (32). Thus, identification of patients with strong
genetic risk and implementation of preventive measures are of
considerable importance. Our findings support a key role for
EPO in genetic susceptibility to PDR and ESRD and identify a
Fig. 3. Effects of the rs1617640 variants on luciferase reporter expression in
cultured HEK 293 cells. pGL3 luciferase reporter recombinant plasmids con-
taining an EPO promoter sequence with the risk allele T (T construct) or
wild-type G allele (G construct) at SNP rs1617640 were transfected into HEK
293 cells. Additionally, pGL3 luciferase reporter recombinant plasmids con-
taining mutated alleles C or A, or the deletion of this nucleotide (DEL) and a
shorter promoter sequence without rs1617640 (short), and the pGL3-Basic
vector without insert (Negative) were transfected into HEK 293 cells. Renilla
luciferase plasmid pTK-RL was cotransfected with each construct as an internal
control for normalization. Normalized luciferase activity was measured in 12
independent experiments. The mean SD is given for each construct. Signif-
icance was examined by using SPSS’s independent sample t test.
Fig. 4. Real-time RT-PCR semiquantitative analysis of EPO mRNA levels. (A)
EPO mRNA levels derived from kidneys of three db/db mice and two normal
littermate controls at 2 months of age. (B) EPO mRNA levels derived from
retina of five mice with oxygen-induced retinal neovascularization (OIR
model) and four control mice at postnatal day 17. Each RT-PCR was assayed in
triplicate. Significance was examined by using SPSS’s independent samples t
test.






potentially pathogenetic mechanism for advanced diabetic eye
and kidney complications.
Materials and Methods
Cases and Controls. This study was approved by the GoKinD Access Committee,
University of Utah, and Joslin Diabetic Center Institutional Review Boards. All
subjects provided informed consent before participation. The GoKinD study is a
collection of North American probands with T1D, with and without diabetic
nephropathy. Presence or absence of retinopathy has been documented in most
participating individuals. Panretinal laser treatment is used as an indication of
PDR. Details of the GoKinD study are available online (www.jdrf.org/gokind) and
are published (16). Boston patients were diagnosed and enrolled at the Joslin
Diabetic Center, and Utah patients were diagnosed and enrolled at the Moran
Eye Center and renal dialysis facilities of the University of Utah. The Boston and
GoKinD cohorts were collected independently. All patients are Americans of
European descent.
Patients underwent detailed eye examinations using the Early Treatment
of Diabetic Retinopathy Study (ETDRS) protocol of seven-standard-field ste-
reoscopic fundus photography. Retinopathy status was determined by eval-
uation of fundus photographs and graded according to clinical ETDRS criteria
[no retinopathy, mild nonproliferative diabetic retinopathy (NPDR), moder-
ate NPDR, severe NPDR, very severe NPDR, PDR less than high risk, and PDR
with high risk characteristics]. Patients with any disk neovascularization,
neovascularization elsewhere, vitreous hemorrhage, fibrovascular prolifera-
tion, or tractional retinal detachment were considered to have PDR. Retinop-
athy grading was performed without prior knowledge of genotypes. The
Boston and Utah diabetic controls enrolled individuals with T1D or T2D for a
minimum of 15 years without any nephropathy or retinopathy. A subject was
considered to have definite diabetic nephropathy if he/she had proteinuria
with a urine albumin to creatinine ratio 300 (normal range 30) or ESRD,
defined as Stage V chronic kidney disease on dialysis or renal transplantation.
The case subjects had both ESRD and a history of PDR unless indicated
otherwise. Patient characteristics of the cohorts are listed in Table S1.
Genotyping. Genomic DNA was extracted from peripheral blood leukocytes.
We selected 19 SNPs from 11 candidate genes of angiogenesis based on
International HapMap Center d’Etude du Polymorphisme Humain data. Initial
genotyping was carried out in the Utah T2D cohort. SNP rs1617640, which
showed association based on initial analysis, was genotyped in the GoKinD
and Boston T1D cohorts. To investigate haplotype structure within the EPO
region, 16 additional tagging, coding, or potentially functional SNPs in EPO
and adjacent genes (10 SNPs in EPO, 3 SNPs in POP7, and 3 SNPs in ZAN) were
genotyped in the Utah T2D cohort. A complete list of primers used for each
SNP is listed in Table S7.
All SNPs were genotyped by using single-nucleotide primer extension assay
(ABI Prism SNaPShot Multiplex Kit, Applied Biosystems) on an ABI 3130xl
genetic analyzer as previously described (36) and according to manufacturer’s
instructions.
Genotyping Error Rate. All SNPs reported in this manuscript had a genotyping
success rate98% and accuracy99% as judged by regenotyping using PCR
product sequencing of 20% of samples in all three cohorts.
Statistical Analysis. All SNP genotyping results were screened for deviations
from Hardy–Weinberg equilibrium, and no SNPs showed significant deviation
(P0.01). The2 test for trend for an additive model or dominant allele model
over alleles was performed to assess evidence for association by using PEPI
version 4.0 (37). Odds ratios and 95% confidence intervals were calculated by
using SPSS version 13.0 to estimate disease risk for heterozygotes and ho-
mozygotes. Linkage disequilibrium (LD) structure was examined by using
Haploview (version 3.32) (38). Default settings were used, creating 95%
confidence bounds on D ’ and R2 to define pairwise SNPs in strong LD (39).
Haploview was also used for allelic association tests.
MatInspector Analysis. The possible transcription factor (TF) binding sites were
examined in rs1617640 variants by using positional weighting matrices extracted
from MatInspector (www.genomatix.de/cgi-bin/matinspectorprof/matfam.pl).
ELISA. Undiluted human vitreous samples were obtained at the time of pars
plana vitrectomy surgery for indications of epiretinal membranes, or macular
hole from nondiabetic patients. The concentration of EPO in human vitreous
body was measured by using a sandwich ELISA. Polyclonal anti-EPO antibody
(R&D Systems) was coated on poly(vinyl chloride) microtiter wells in carbon-
ate/bicarbonate buffer (pH 9.6, 0.05 M) at 4°C overnight. After washing,
remaining protein-binding sites were blocked with 10% goat serum at room
temperature for 2 h. Twenty-five microliters of vitreous sample, or EPO
standard sample (Cell Sciences) at different concentrations and 75 l of 10%
goat serum were added to each well and the plate was placed on a horizontal
shaker at room temperature for 1 h. After washing, monoclonal anti-EPO
antibody (R&D Systems) and horseradish peroxidase-conjugated goat anti-
mouse IgG antibody (Santa Cruz Biotechnology) were added. Finally, 3,3,5,5-
tetramethylbenzidine (TMB) solution was added to develop color. Absor-
bance was read at 655 nm by a Benchmark Plus microplate reader (Bio-Rad)
and the EPO concentration was calculated from a standard curve.
Luciferase Reporter Assays. A DNA fragment containing base pairs 1357 to
	180 relative to the EPO transcription site including either the G (G construct)
or T allele (T construct) of rs1617640 at 1125 was PCR amplified from
genomic DNA of a normal individual by using the following primers: forward,
CGGGGTACCAACTCCTGGGCTCAAAGGAT; reverse, CCGCTCGAGTCCGCGCCT-
GGCCGGGGTCCCTCAG (Fig. S2). Three other constructs with altered alleles (A,
C, or deletion) at rs1617640 were also created. A DNA fragment containing
base pairs 963 to 	180 relative to the EPO transcription site without
rs1617640 [Promoter (short)] was PCR amplified from genomic DNA of the
same individual by using the following primers: forward, CGGGGTACCCCTG-
CACAATGGACTGTGTGCTCTG; reverse, CCGCTCGAGTCCGCGCCTGGC-
CGGGGTCCCTCAG. These constructs were subcloned into the KpnI–XhoI site
of the pGL3-basic vector (Promega). All constructs were verified by restriction
enzyme digestion and complete bidirectional DNA sequencing. We confirmed
that the only difference between the T and G construct was T or G at rs1617640
and the rest of the EPO promoter sequence was identical to that of native
human EPO promoter sequence. A positive control plasmid (pGL3-Control
Vector) containing a SV40 enhancer and promoter driving luciferase reporter
was obtained from Promega.
HEK 293 cells were split into 24-well plates and cotransfected 24 h later with
1 ng of the transfection control Renilla luciferase plasmid pTK-RL (Promega)
and 200 ng of one of the following plasmids: pGL3-control plasmid, promoter
(short) plasmid, promoter (G) construct, promoter (T) construct, promoter (A),
promoter (C) and rs1617640 deletion (DEL) constructs. Transfections (n  12)
were done by using the Fugene-6 protocol according to the supplier’s speci-
fications (Roche Applied Science). Forty-eight hours after transfection, cells
were washed with PBS twice and luciferase activities were measured with the
Dual-Luciferase Assay Kit (Promega). Fold induction was derived relative to
normalized reporter activity.
EPO mRNA Level in Oxygen-Induced Retinopathy (OIR) Mouse Model and db/db
Mouse Model. Retinal neovascularization was produced in C57BL/6 mice by
placing postnatal day 7 (P7) mice and their mothers in an atmosphere of 75
3% oxygen for 5 days (40). Oxygen concentration was automatically moni-
tored and controlled by an oxygen controller (BioSpherix). At P12, the mice
were returned to room air for 5 days. At P17 the mice were killed and their eyes
were rapidly removed and dissected. The retina was removed and EPO mRNA
levels were measured by RT-PCR .
The db/db mice are among the best characterized and most intensively
investigated mouse models for diabetic kidney disease (21). Animals were
obtained from The Jackson Laboratory. Two-month-old db/db mice were
killed, their kidneys were rapidly removed, and EPO mRNA levels were mea-
sured by RT-PCR.
Total RNA was isolated from retinas of the OIR mice and littermate controls
and from the kidney of db/db mice and littermate controls. The RNA was
converted into cDNA (Invitrogen, SuperScript III First-Strand Synthesize System
for RT-PCR, catalog no. 18080-051). Fifty nanograms of cDNA was used for
real-time PCR (Qiagen, QuantiTect SYBR Green PCR Kit) with the following
primers (Mus-EPO-qPCR-L, CCACCCTGCTGCTTTTACTC/Mus-EPO-qPCR-R, CT-
CAGTCTGGGACCTTCTGC) for the mouse EPO gene to generate a 166-bp
product. GAPDH expression (Mus-GAPDH-QPCR-L2, GTGAAGGTCGGTGT-
GAACGG/Mus-GAPDH-QPCR-R2, GCCGTTGAATTTGCCGTGAG) was used to
normalize EPO expression. The RT-PCR was performed simultaneously for EPO
andGAPDH on an ABI 7300 real-time PCR system. RT-PCR conditions were one
cycle of 50°C for 2 min, 95°C for 15 min, followed by 35 cycles in which each
cycle included 94°C for 15 sec, 58°C for 30 sec, and 72°C for 30 sec.
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